Stockscreener 앱 받기
4.22
0.47%
-0.02
시간 외 거래:
4.23
0.01
+0.24%
전일 마감가:
$4.24
열려 있는:
$4.35
하루 거래량:
6.07M
Relative Volume:
0.98
시가총액:
$912.27M
수익:
$76.20M
순이익/손실:
$-17.37M
주가수익비율:
463.74
EPS:
0.0091
순현금흐름:
$-75.81M
1주 성능:
-4.09%
1개월 성능:
-26.99%
6개월 성능:
+48.59%
1년 성능:
+586.07%
1일 변동 폭
$4.08
$4.47
1주일 범위
$4.08
$5.15
52주 변동 폭
$0.40
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
4.22 | 916.59M | 76.20M | -17.37M | -75.81M | 0.0091 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2026-01-20 | 개시 | Guggenheim | Buy |
| 2025-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
Jefferies Maintains Buy on CytomX Therapeutics, Inc. (CTMX) $16 PT Mar 2026 - Meyka
Jefferies reiterates Buy rating on CytomX stock after phase 1 data - Investing.com Canada
CytomX Therapeutics (NASDAQ:CTMX) Given New $12.00 Price Target at Piper Sandler - MarketBeat
CTMX: Piper Sandler Raises Price Target to $12 | CTMX Stock News - GuruFocus
Piper Sandler raises CytomX stock price target on drug trial data - Investing.com Canada
CytomX Therapeutics launches $250M public offering - MSN
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data - AOL.com
How Investors Are Reacting To CytomX Therapeutics (CTMX) Equity Raise And Encouraging Varseta-M Trial Data - Sahm
A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results - Yahoo Finance
Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16 - Insider Monkey
CytomX Therapeutics prices $250M public offering at $5.30 per share - MSN
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
Cytomx Therapeutics Insider Sold Shares Worth $764,138, According to a Recent SEC Filing - marketscreener.com
CTMX Stock Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill
Yu-Waye Chu Sells 21,279 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock - MarketBeat
Sean Mccarthy Sells 118,969 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock - MarketBeat
Sean McCarthy, CytomX Therapeutics CEO, sells $764k in stock By Investing.com - Investing.com Canada
CytomX therapeutics (CTMX) chief medical officer sells $136k in stock - Investing.com Canada
CytomX Therapeutics (NASDAQ:CTMX) CFO Sells $124,053.66 in Stock - MarketBeat
Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) SVP Sells 31,492 Shares of Stock - MarketBeat
CytomX (CTMX) CMO sells 21,279 shares to cover RSU tax obligations - Stock Titan
CytomX Therapeutics SVP Belvin sells $202k in stock By Investing.com - Investing.com Australia
Ogden, CytomX Therapeutics CFO, sells $124k in shares - Investing.com
CytomX Therapeutics SVP Belvin sells $202k in stock - Investing.com
CytomX Therapeutics (CTMX) CEO sells shares to cover RSU tax obligations - Stock Titan
Tax-driven share sale by CytomX (CTMX) chief scientist on RSU vesting - Stock Titan
CytomX Therapeutics (CTMX) reports Q4 loss, misses revenue estimates - MSN
CytomX (NASDAQ: CTMX) CFO sells 19,323 shares for tax withholding - Stock Titan
CytomX Therapeutics Raises $234 Million in Equity Offering - TipRanks
Why Is CytomX Therapeutics Stock Falling On Wednesday? - Sahm
CytomX prices $5.30 public offering to raise ~$234.4M; includes pre-funded warrants - TradingView
CytomX (NASDAQ: CTMX) prices $234.4M stock and pre-funded warrant deal - Stock Titan
CytomX Therapeutics (NASDAQ:CTMX) Given New $16.00 Price Target at Barclays - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade - MarketBeat
CTMX Sees Price Target Raised to $16 by Jefferies Today | CTMX S - GuruFocus
Jefferies Maintains Buy on CTMX (CytomX Therapeutics) March 18, 2026 - Meyka
Latham Watkins Advises CytomX Therapeutics on Offering of Common Stock Pre Funded Warrants - Latham & Watkins LLP
CytomX (NASDAQ: CTMX) offers 45.99M shares and 1.18M pre‑funded warrants - Stock Titan
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
Analysts bullish ahead of colorectal cancer readout for CytomX Therapeutics, Inc. (CTMX) - MSN
CytomX Stocks Slide Amidst Profit Woes and Revenue Shortfall - timothysykes.com
CytomX Therapeutics (CTMX) Gets Price Target Boost from Guggenhe - GuruFocus
CTMX: Key Managers in Recent Offering - GuruFocus
Barclays raises its price target on CytomX Therapeutics, Inc. (CTMX) to $10 and maintains an overweight rating - MSN
CytomX Therapeutics (NASDAQ:CTMX) Sees Strong Trading Volume Following Analyst Upgrade - MarketBeat
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level - Seeking Alpha
CytomX Therapeutics (NASDAQ:CTMX) Price Target Raised to $15.00 at Guggenheim - MarketBeat
HC Wainwright Has Bearish Estimate for CTMX Q1 Earnings - MarketBeat
CytomX Therapeutics Prices $250 Million Securities Offering; Shares Up Pre-Bell - marketscreener.com
CytomX prices $250M stock offering at $5.30 per share By Investing.com - Investing.com South Africa
CytomX Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):